Strong Memorial Hospital is among a select few in the U.S. offering Carvykti, a treatment for multiple myeloma, a cancer in ...

A new research project is aiming to uncover why some cases of myeloma are more aggressive and harder to treat. The three-year study, led by Dr John Jones at Brighton and Sussex Medical School and ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

EXCLUSIVE: A top doctor has shared five common symptoms which could be a sign that something is seriously wrong.

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

An enzyme type noted in several cancers is the family of adenosine deaminases acting on RNA (ADARs). These enzymes convert ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

It represents an aggressive form of MM and occurs when myeloma cells spread and form tumours (plasmacytomas) in areas such as ...

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

UK's health authorities will offer a new targeted treatment for patients suffering from an aggressive blood cancer. This ...